利用TCGA数据集分析E2F7在肺腺癌中的表达及临床意义

Abstract
Figure/Table
References (17)
Related Citation (9)

Download: PDF (0 KB) HTML (28 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the expression and clinical significance of transcription factor E2F7 in lung adenocarcinoma and its adjacent tissues.Methods The RNAseq data of 337 cases of lung adenocarcinoma tissues(tumor group)and 59 cases of paracancer tissues(para-cancer control group)and the corresponding clinical data of lung adenocarcinoma patients were downloaded from the cancer genome atlas(TCGA)database,and the expression of E2F7 in the data set was analyzed and processed.The correlation between E2F7 expression and clinicopathological features of lung adenocarcinoma and its influence on the prognosis were analyzed and compared,and evaluate independent risk factors for the prognosis in patients with lung adenocarcinoma through the COX risk ratio model.Results The expression level of E2F7 in the tumor group was significantly higher than that in the para-carcinoma control group(P<0.05).T Stage,N Stage and Stage were relevant factors in E2F7 expression(P<0.05).Survival analysis showed that patients with high expression of E2F7 in lung adenocarcinoma had a poor prognosis(P<0.05).The results of the multivariate COX risk ratio model results showed that high E2F7 expression level and Stage were independent risk factors for poor prognosis in patients with lung adenocarcinoma(P<0.05).Conclusion E2F7 may promote the occurrence and development of lung adenocarcinoma through various ways,thus affecting the prognostic survival of patients with lung adenocarcinoma.Therefore,E2F7 can be used as a prognostic marker or potential therapeutic target for patients with lung adenocarcinoma.

Key words： E2F7 Lung adenocarcinoma Cancer genome map Prognostic marker

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAO Qiu-rong
	GUO Jing
	CHEN Liang-yuan

Cite this article:

ZHAO Qiu-rong,GUO Jing,CHEN Liang-yuan. Analysis of the expression and clinical significance of E2F7 expression in lung adenoarinoma utilizing TCGA datasets[J]. 中国当代医药, 2021, 28(27): 130-132.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I27/130

[1]	Bray F，Ferlay J，Soerjomataram I，et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin，2018，68（6）：394-424.
[2]	Siegel RL，Miller KD，Jemal A.Cancer statistics，2016[J].CA Cancer J Clin，2016，66（1）：7-30.
[3]	Chen WQ，Zheng RS，Baade PD，et al.Cancer statistics in China 2015[J].CA Cancer J Clin，2016，66（2）：115-132.
[4]	Sun CC，Li SJ，Hu W，et al.Comprehensive Analysis of the Expression and Prognosis for E2Fs in Human Breast Cancer[J].Mol Ther，2019，27（6）：1153-1165.
[5]	Attwooll C，Lazzerini DE，Helin K.The E2F family：specific functions and overlapping interests[J].EMBO J，2004，23（24）：4709-4716.
[6]	Chen HZ，Tsai SY，Leone G.Emerging roles of E2Fs in cancer：an exit from cell cycle control[J].Nat Rev Cancer，2009，9（11）：785-797.
[7]	Weijts BGMW，Westendorp B，Hien BT，et al.Atypical E2Fs inhibit tumor angiogenesis[J].Oncogene，2018，37（2）：271-276.
[8]	Emmrich S，Pützer BM.Checks and balances：E2F-microRNA crosstalk in cancer control[J].Cell Cycle，2010，9（13）：2555-2567.
[9]	HutterC，ZenklusenJC.TheCancerGenomeAtlas：Creating Lasting Value beyondIts Data[J].Cell，2018，173（2）：283-285.
[10]	Ding L，Bailey MH，Porta-Pardo E，et al.Perspective on Oncogenic Processes at theEnd ofthe Beginning of Cancer Genomics[J].Cell，2018，173（2）：305-320.
[11]	Wang Z，Jensen MA，Zenklusen JC.A Practical Guide to The Cancer Genome Atlas（TCGA）[J].Methods Mol Biol，2016，1418：111-141.
[12]	Sanchez-Vega F，Mina M，Armenia J，et al.Oncogenic Signaling Pathways in The Cancer Genome Atlas[J].Cell，2018，173（2）：321-337.
[13]	Malta TM，Sokolov A，Gentles AJ，et al.Machine Learning Identifies StemnessFeatures Associatedwith Oncogenic Dedifferentiation[J].Cell，2018，173（12）：338-354.
[14]	Yang R，Wang M，Zhang G，et al.E2F7-EZH2 axis regulates PTEN/AKT/mTOR signalling and glioblastoma progression[J].Br J Cancer，2020，123（9）：1445-1455.
[15]	Yao H，Lu F，Shao Y.The E2F family as potential biomarkers and therapeutic targets in colon cancer[J].Peer J，2020，8：e8562.
[17]	Dimova DK，Dyson NJ.The E2F transcriptional network：old acquaintances with new faces[J].Oncogene，2005，24（17）：2810-2826.
[16]	Sun CC，Zhou Q，Hu W，et al.Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma[J].Aging（Albany NY），2018，10（5）：973-987.